文献速递脑血管病外科神经重症

动脉瘤性蛛网膜下腔出血后颅内给予尼卡地平:文献综述

Intracranial Administration of Nicardipine After Aneurysmal Subarachnoid Hemorrhage: A Review of the Literature.
PubMed 文献 · World Neurosurg · 2019-01-29

本文系统综述1994至2018年PubMed文献,共纳入17项研究(含3项动物研究),评估鞘内、脑室内及脑池内给予尼卡地平治疗动脉瘤性蛛网膜下腔出血后血管痉挛的效果。研究一致显示鞘内尼卡地平可逆转血管痉挛,但部分研究显示效应局限于给药部位附近;长期临床结局数据不一,不良事件包括头痛、脑膜炎和脑积水。作者认为该给药途径可作为血管痉挛的治疗辅助手段,尤其对常规治疗无效者,但需更大规模对照临床试验。

要点

  • 鞘内尼卡地平可逆转动脉瘤性蛛网膜下腔出血后血管痉挛,但部分研究中效应局限于给药部位附近。
  • 长期临床结局数据不一,部分研究显示明显改善,部分研究未显示优于标准治疗。
  • 鞘内和脑室内给药相关不良事件包括头痛、脑膜炎和脑积水,但不良后果不常见。

核心结论

  • 鞘内、脑室内及脑池内(植入剂)给予尼卡地平可作为动脉瘤性蛛网膜下腔出血后血管痉挛的治疗辅助手段,尤其对常规治疗无效的病例,但需更大规模对照临床试验。

研究设计与样本

  • 系统综述,按照PRISMA指南通过PubMed检索1994年至2018年发表的文献,检索词包括「intrathecal nicardipine」「intraventricular nicardipine」和「nicardipine prolonged-release」的多种组合,共纳入17项研究,其中3项为动物研究。

主要发现

  • 研究一致显示鞘内尼卡地平成功逆转血管痉挛,但部分研究显示效应局限于药物释放部位附近。
  • 长期临床结局数据不一,部分研究显示明显改善,而其他研究未能显示与接受标准治疗的患者相比结局改善。
  • 不良后果不常见,但鞘内和脑室内给药及治疗与不良事件相关,包括头痛、脑膜炎和脑积水。

临床怎么用

  • 作者认为鞘内、脑室内及脑池内(植入剂)给予尼卡地平可作为动脉瘤性蛛网膜下腔出血后血管痉挛的治疗辅助手段,尤其对常规治疗无效的病例。
  • 作者指出需要更大规模对照临床试验。

局限性

  • 长期临床结局数据不一,部分研究显示明显改善而其他研究未能显示与标准治疗相比结局改善。
  • 部分研究显示鞘内尼卡地平的效应局限于药物释放部位附近。
  • 作者指出需要更大规模对照临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intrathecal (IT), intraventricular (IVt), and intracisternal administration of nicardipine deliver treatment directly into the central nervous system. This route of drug delivery is being investigated as a potential treatment of vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). OBJECTIVE: The authors reviewed the existing literature regarding the direct administration of nicardipine into the intracranial space for the treatment of vasospasm following aSAH. METHODS: An electronic search of literature published between 1994 and 2018 was performed using PubMed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. A variety of combinations of the search terms "intrathecal nicardipine," "intraventricular nicardipine," and "nicardipine prolonged-release" were used. RESULTS: A total of 17 studies were included in this systematic review, 3 of which were studies in animals. The studies consistently demonstrated that IT nicardipine successfully reverses vasospasm, but the effect, as shown in some studies, was limited to the immediate vicinity of drug release. The data regarding long-term clinical outcomes are variable, with some studies demonstrating marked improvement whereas others fail to demonstrate improved outcomes when compared with patients who receive standard of care. Although adverse sequalae were uncommon, IT and IVt administration and therapy were associated with adverse effects including headache, meningitis, and hydrocephalus. CONCLUSIONS: Given the findings presented in these studies, IT, IVt, and intracisternal (pellet) nicardipine administration can be useful treatment adjuncts for vasospasm following aSAH, especially in cases refractory to conventional forms of treatment. However, larger, controlled clinical trials are warranted.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Dodson V, Majmundar N, El-Ghanem M, et al. Intracranial Administration of Nicardipine After Aneurysmal Subarachnoid Hemorrhage: A Review of the Literature. World Neurosurg. 2019. PMID: 30708083. doi:10.1016/j.wneu.2019.01.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。